🇺🇸 FDA
Patent

US 7060827

Intermediates useful for making 2,4-pyrimidinediamine compounds

granted A61KA61K31/505A61K31/506

Quick answer

US patent 7060827 (Intermediates useful for making 2,4-pyrimidinediamine compounds) held by Rigel Pharmaceuticals, Inc. expires Mon Jun 08 2026 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Jun 13 2006 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 08 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K31/505, A61K31/506, A61K31/519, A61K31/5377